Literature DB >> 28017598

Biodegradable poly-ε-caprolactone microcarriers for efficient production of human mesenchymal stromal cells and secreted cytokines in batch and fed-batch bioreactors.

Alan Tin-Lun Lam1, Jian Li2, Jessica Pei-Wen Toh2, Eileen Jia-Hui Sim3, Allen Kuan-Liang Chen3, Jerry Kok-Yen Chan4, Mahesh Choolani5, Shaul Reuveny3, William R Birch2, Steve Kah-Weng Oh6.   

Abstract

Large numbers of human mesenchymal stromal cells (MSCs) used for a variety of applications in tissue engineering and cell therapy can be generated by scalable expansion in a bioreactor using microcarriers (MCs) systems. However, the enzymatic digestion process needed to detach cells from the growth surface can affect cell viability and potentially the potency and differentiation efficiency. Thus, the main aim of our study was to develop biocompatible and biodegradable MCs that can support high MSC yields while maintaining their differentiation capability and potency. After cell expansion, the cells that covered MCs can be directly implanted in vivo without the need for cell harvesting or use of scaffold. Poly-ε-caprolactone (PCL) is known as a biocompatible and biodegradable material. However, it cannot be used for generation of MCs because its high density (1.14 g/cm3) would exclude its applicability for suspension MCs in stirred reactors. In this article, we describe expansion and potency of MSCs propagated on low-density (1.06 g/cm3) porous PCL MCs coated with extracellular matrices (LPCLs) in suspended stirred reactors. Using these LPCLs, cell yields of about 4 × 104 cells/cm2 and 7- to 10-fold increases were obtained using four different MSC lines (bone marrow, cord blood, fetal and Wharton's jelly). These yields were comparable with those obtained using non-degradable MCs (Cytodex 3) and higher than two-dimensional monolayer (MNL) cultures. A fed-batch process, which demonstrated faster cell expansion (4.5 × 104 cells/cm2 in 5 days as compared with 7 days in batch culture) and about 70% reduction in growth media usage, was developed and scaled up from 100-mL spinner flask to 1-L controlled bioreactor. Surface marker expression, trilineage differentiation and clonogenic potential of the MSCs expanded on LPCL were not affected. Cytokine secretion kinetics, which occurred mostly during late logarithmic phase, was usually comparable with that obtained in Cytodex 3 cultures and higher than MNL cultures. In conclusion, biodegradable LPCL can be used to efficiently expand a variety of MSC lines in stirred scalable reactors in a cost-effective manner while maintaining surface markers expression, differentiation capability and high levels of cytokine secretion. This study is the first step in testing these cell-biodegradable porous MC aggregates for tissue engineering and cell therapy, such as bone and cartilage regeneration, or wound healing.
Copyright © 2017 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Mesenchymal stromal cells; bioreactors; cytokines; microcarriers

Mesh:

Substances:

Year:  2016        PMID: 28017598     DOI: 10.1016/j.jcyt.2016.11.009

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  16 in total

Review 1.  Diabetes complications and extracellular vesicle therapy.

Authors:  Setareh Soltani; Kamran Mansouri; Shahram Parvaneh; Avnesh S Thakor; Flemming Pociot; Reza Yarani
Journal:  Rev Endocr Metab Disord       Date:  2021-10-14       Impact factor: 6.514

2.  Development of a novel feeding regime for large scale production of human umbilical cord mesenchymal stem/stromal cells.

Authors:  Yichen Dai; Xiaolin Cui; Ge Zhang; Ali Mohsin; Huiming Xu; Yingping Zhuang; Meijin Guo
Journal:  Cytotechnology       Date:  2022-03-10       Impact factor: 2.040

Review 3.  Manufacturing of primed mesenchymal stromal cells for therapy.

Authors:  James Q Yin; Jun Zhu; James A Ankrum
Journal:  Nat Biomed Eng       Date:  2019-01-28       Impact factor: 25.671

Review 4.  Mesenchymal stromal cells for the treatment of ocular autoimmune diseases.

Authors:  Joo Youn Oh; Ryang Hwa Lee
Journal:  Prog Retin Eye Res       Date:  2021-03-26       Impact factor: 21.198

Review 5.  Bioengineering Outlook on Cultivated Meat Production.

Authors:  Ivana Pajčin; Teodora Knežić; Ivana Savic Azoulay; Vanja Vlajkov; Mila Djisalov; Ljiljana Janjušević; Jovana Grahovac; Ivana Gadjanski
Journal:  Micromachines (Basel)       Date:  2022-02-28       Impact factor: 2.891

Review 6.  Engineering microenvironments for manufacturing therapeutic cells.

Authors:  Brian J Kwee; Kyung E Sung
Journal:  Exp Biol Med (Maywood)       Date:  2021-07-11

Review 7.  Biological Considerations in Scaling Up Therapeutic Cell Manufacturing.

Authors:  Darshana S Cherian; Tejasvini Bhuvan; Laurence Meagher; Tracy S P Heng
Journal:  Front Pharmacol       Date:  2020-05-13       Impact factor: 5.810

Review 8.  Modeling trauma in rats: similarities to humans and potential pitfalls to consider.

Authors:  Birte Weber; Ina Lackner; Melanie Haffner-Luntzer; Annette Palmer; Jochen Pressmar; Karin Scharffetter-Kochanek; Bernd Knöll; Hubert Schrezenemeier; Borna Relja; Miriam Kalbitz
Journal:  J Transl Med       Date:  2019-09-05       Impact factor: 5.531

9.  The cytokine secretion profile of mesenchymal stromal cells is determined by surface structure of the microenvironment.

Authors:  Daniëlle G Leuning; Nick R M Beijer; Nadia A du Fossé; Steven Vermeulen; Ellen Lievers; Cees van Kooten; Ton J Rabelink; Jan de Boer
Journal:  Sci Rep       Date:  2018-05-16       Impact factor: 4.379

10.  Three-Dimensional Culture of Ameloblast-Originated HAT-7 Cells for Functional Modeling of Defective Tooth Enamel Formation.

Authors:  Anna Földes; Thanyaporn Sang-Ngoen; Kristóf Kádár; Róbert Rácz; Ákos Zsembery; Pamela DenBesten; Martin C Steward; Gábor Varga
Journal:  Front Pharmacol       Date:  2021-06-02       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.